^
    Back
    Association details:
    Biomarker:ASXL1 deletion
    Cancer:Myelodysplastic Syndrome
    Drug:azacitidine (DNMT inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Br J Haematol
    Title:

    Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

    Published date:
    07/22/2021
    Excerpt:
    ASXL1DEL /ASXL1MUT patients were correlated by univariable analysis with a worse response to AZA.
    DOI:
    10.1111/bjh.17675